Literature DB >> 31439379

Design, synthesis and biological evaluation of benzamide derivatives as novel NTCP inhibitors that induce apoptosis in HepG2 cells.

Shuangmei Zhao1, Yongqi Zhen1, Leilei Fu1, Feng Gao1, Xianli Zhou1, Shuai Huang2, Lan Zhang3.   

Abstract

Sodium taurocholate cotransport polypeptide (NTCP) plays an important role in the development of hepatitis and acts as a switch to allow hepatitis virus to enter hepatic cells. As the entry receptor protein of hepatitis virus, NTCP is also an effective target for the treatment of hepatocellular carcinoma. Herein, twenty-five benzamide analogues were synthesized based on the virtual screening design and their anti-proliferative activities against HepG2 cells were evaluated in vitro. Compound 35 was found to be promising, with an IC50 value of 2.8 μM. The apoptosis induced by 35 was characterized by the regulation of markers, including an increase in Bax, cleaved-caspase 3, and cleaved-PARP proteins, and a decrease in Bcl-2 protein. Molecular docking and molecular dynamics (MD) simulation confirmed that compound 35 can bind tightly to NTCP. Western blot analysis also showed that NTCP was inhibited. Altogether, these results indicate that compound 35 acts as a novel NTCP inhibitor to induce apoptosis in HepG2 cells.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anti-proliferative activity; Apoptosis; Hepatocellular carcinoma; NTCP inhibitors

Mesh:

Substances:

Year:  2019        PMID: 31439379     DOI: 10.1016/j.bmcl.2019.126623

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  2 in total

1.  Design, Synthesis and Bioactive Evaluation of Oxime Derivatives of Dehydrocholic Acid as Anti-Hepatitis B Virus Agents.

Authors:  Zhuocai Wei; Jie Tan; Xinhua Cui; Min Zhou; Yunhou Huang; Ning Zang; Zhaoni Chen; Wanxing Wei
Journal:  Molecules       Date:  2020-07-24       Impact factor: 4.411

2.  MicroRNA-326 impairs chemotherapy resistance in non small cell lung cancer by suppressing histone deacetylase SIRT1-mediated HIF1α and elevating VEGFA.

Authors:  Jinying Wei; Guangping Meng; Jing Wu; Ying Wang; Qiang Zhang; Ting Dong; Jin Bao; Chunyan Wang; Jie Zhang
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.